Targacept
Targacept admits failure in Alzheimer’s trial
July 15, 2014Research and Development, Sales and Marketing Alzheimer's, Aricept, Pfizer, TC-173, Targacept
Targacept is dropping a once promising Alzheimer’s drug from further clinical trials after it failed to beat Pfizer’s Aricept (donepezil) …
Targacept appoints chairman
January 28, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept, richard
Clinical-stage biopharma firm Targecept has appointed its non-executive director since 2002 John Richard to be its chairman of the board. …
Targacept makes changes to Board and management
March 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept
Clinical-stage biopharma firm Targacept has announced several changes to its Board of directors and management. By the end of May …
Targacept confirms Stephen Hill as president and chief executive
November 27, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept, stephen hill
Clinical-stage biopharma firm Targacept has announced that Stephen Hill has been appointed as president and chief executive. Hill is expected …
AstraZeneca to take Alzheimer’s drug into phase II
January 5, 2012Research and Development Alzheimer's, AstraZeneca, Targacept
AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …
GSK ends neuroscience research alliance
March 7, 2011Research and Development GSK, GlaxoSmithKline, Targacept, neuronal nicotinic receptors, neuroscience research
GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. GSK forked out $45 million …
AZ-Targacept depression candidate moves into phase IIb
February 9, 2011Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder
AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …
AstraZeneca and Targacept begin depression trials
June 24, 2010Research and Development AstraZeneca, Targacept, depression
AstraZeneca and Targacept have begun enrolling patients in phase III trials for TC-5214, a new treatment for depression. The new …
AZ licences late-stage depression candidate
December 8, 2009Sales and Marketing AZ, Targacept, depression
AstraZeneca is to pay $200 million up front for rights to a late-stage developmental drug aimed at sufferers from depression …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
